Skip to main content

Oaktree Acquisition Corp. III Life Sciences

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

OACC$10.70-0.2%Stored close · as of Nov 5, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Item 15.Exhibits, Financial Statement Schedules
(a)The following documents are filed as part of this Report:
(1)Financial Statements

See “Index to Financial Statements” at “Item 8. Financial Statements and Supplementary Data” in this Report.

(2)Financial Statement Schedules

None.

(3)Exhibits

We hereby file or furnish, as applicable, as part of this Report the exhibits listed in the below exhibit index:

Exhibit No.Description
3.1Amended and Restated Memorandum and Articles of Association.(1)
4.1Specimen Unit Certificate.(2)
4.2Specimen Ordinary Share Certificate.(2)
4.3Specimen Warrant Certificate.(2)
4.4Warrant Agreement, dated October 25, 2024, by and between Continental Stock Transfer & Trust Company and the Registrant.(1)
4.5Description of Registrant’s Securities.*
10.1Private Placement Placement Units Purchase Agreement, dated October 23, 2024, by and between the Registrant and the Sponsor.(1)
10.2Investment Management Trust Agreement, dated October 25, 2024, by and between Continental Stock Transfer & Trust Company and the Registrant.(2)
10.3Registration and Shareholder Rights Agreement, dated October 25, 2024, by and among the Registrant, the Sponsor and certain other equityholders named therein.(2)
10.4Letter Agreement, dated October 23, 2024, by and among the Registrant, the Sponsor and the Registrant’s officers and directors.(2)
10.5Administrative Services and Indemnification Agreement, dated October 25, 2024, by and between the Registrant and the Sponsor.(2)
10.6Form of Indemnity Agreement.(1)
10.7Promissory Note, dated as of July 15, 2024, issued to Oaktree Acquisition Holdings III LS, L.P.(2)
10.8Assignment of Promissory Note Agreement, dated September 9, 2024, between the Sponsor, Oaktree Acquisition Holdings III LS, L.P. and the Registrant.(2)
10.9Securities Subscription Agreement, dated July 15, 2024, between the Registrant and Oaktree Acquisition Holdings III LS, L.P.(2)
10.10Transfer and Assignment of Securities Subscription Agreement, dated September 9, 2024, between the Sponsor, Oaktree Acquisition Holdings III LS, L.P. and the Registrant.(2)
10.11Underwriting Agreement, dated October 23, 2024, by and among the Registrant and Jefferies LLC, Citigroup Global Markets Inc. and UBS Securities LLC, as representatives of the several underwriters named therein.(1)
19Insider Trading Policy.*
21Subsidiaries of the Company.*
31.1Certification of the Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).*
31.2Certification of the Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).*
32.1Certification of the Chief Executive Officer required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350.**
32.2Certification of the Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350.**
97Clawback Policy.*
*Filed herewith
**Furnished herewith.
(1)Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed with the SEC on October 25, 2024.
(2)Incorporated by reference to the Registrant’s Registration Statement on Form S-1, filed with the SEC on October 4, 2024.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.